Name (Synonyms) | Correlation | |
---|---|---|
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.21 |
There is one clinical trial.
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.
Description: mortality of any cause
Measure: All-cause mortality Time: During 1 year follow-upDescription: mortality of any cause
Measure: 30-day mortality Time: Within 30 days after inclusionDescription: Myocardial infarction, stroke, or CV death
Measure: Major adverse cardiovascular events Time: During 1 year follow-up